Xiuwang Huang - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Xiuwang Huang

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Bioorganic & Medicinal Chemistry|July 13, 2022

Discovery of CN0 as a novel proteolysis-targeting chimera (PROTAC) degrader of PARP1 that can activate the cGAS/STING immunity pathway combined with daunorubicinShanshan Lin, Guihui Tu, Zelei Yu, et al.

European Journal of Medicinal Chemistry|December 5, 2021

Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancerQuanyu Liu, Guihui Tu, Yan Hu, et al.

Journal of Drug Targeting|March 3, 2023

Albumin-encapsulated HSP90-PROTAC BP3 nanoparticles not only retain protein degradation ability but also enhance the antitumour activity of BP3 <i>in vivo</i>Qingna Jiang, Yan Hu, Quanyu Liu, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Bioorganic & Medicinal Chemistry|July 13, 2022

European Journal of Medicinal Chemistry|December 5, 2021

Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancerQuanyu Liu, Guihui Tu, Yan Hu, et al.

Journal of Drug Targeting|March 3, 2023

Albumin-encapsulated HSP90-PROTAC BP3 nanoparticles not only retain protein degradation ability but also enhance the antitumour activity of BP3 <i>in vivo</i>Qingna Jiang, Yan Hu, Quanyu Liu, et al.

Pageof 2